Fujifilm commences Phase III trial of influenza drug Avigan for Covid-19

1 April 2020 (Last Updated April 1st, 2020 11:07)

Fujifilm Toyama Chemical has started a Phase III clinical trial of its antiviral influenza drug Avigan (favipiravir) for the treatment of Covid-19 patients in Japan.

Avigan specifically blocks RNA polymerase associated with influenza viral replication.

The mechanism is expected to have an antiviral effect on SARS-CoV-2, the novel coronavirus that causes Covid-19.

Read the full article here